Gene therapy for diabetic macular swelling affecting vision
Part of Eyes & vision, Hormones & metabolism clinical trials.
This early-stage (Phase 1) study tests a new gene therapy to improve vision for adults with diabetic macular edema. It mainly looks at whether the treatment can be safely given and may help your vision over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be at least 18 years old and willing to follow all study steps
- Have a confirmed diagnosis of diabetic macular edema affecting the eye being studied
- Have HbA1c of 10% or less (a diabetes blood sugar test)
- Your eye’s vision test (best corrected visual acuity) must be 73 letters or worse
- There can’t be other eye diseases in the studied eye that could affect vision or need treatment during the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a gene therapy for diabetic macular edema (DME), a condition where fluid builds up in the central part of the eye's retina. It aims to improve vision and reduce the need for frequent eye injections.
This trial tests a gene therapy called RGX-314 for people with diabetic macular edema that affects the center of the vision. If you have had previous treatment and still have swelling, this study may be an option.
This Phase 1 trial tests MS-553 to see how it works and how safely it can be given to people with diabetic retinopathy causing central macular swelling (macular edema). You may be considered if your vision and eye scan results match, and if you can follow frequent study visits.
This trial tests a new medication, CU06-1004, for people with diabetic macular edema, a condition that causes blurry vision due to fluid buildup in the central part of the retina. The goal is to see if this drug can reduce the swelling and improve vision.
This study tests different doses of a new medicine (BI 3812465) injected into the eye to treat diabetic macular edema—swelling in the back of the eye caused by diabetes that can blur vision. The trial measures how safe the medicine is and how well patients tolerate it.
This study tests a new drug (RO7823653) given as an eye injection for people with diabetic macular edema, a condition where swelling in the retina harms vision. It aims to see if the drug is safe and how the body processes it.
Hear when a new Diabetic Macular Edema trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.